TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01664507
Drug: conventional dose epinephrine
Normalized name: epinephrine Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: conventional dose epinephrine : 0.5mg/kg + 0.9% normal saline
Study: NCT01664507
Drug: low dose epinephrine
Normalized name: epinephrine Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: low dose epineprhine : 0.1mg/kg + 0.9% normal saline
Study: NCT04513171
Drug: Norditropin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norditropin 245μg/kg/week, subcutaneous injection, Once daily.
Study: NCT03131687
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT03945318
Drug: BION-1301 Single Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: A solution for IV infusion administered as a single dose.
Study: NCT03945318
Drug: Placebo Single Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: A solution by IV infusion administered as a single dose.
Study: NCT03945318
Drug: BION-1301 Multiple Doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: A solution for IV infusion or SC injections (Part 3 only) administered as multiple doses.
Study: NCT03945318
Drug: Placebo Multiple Doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: A solution by IV infusion administered as multiple doses.
Study: NCT03945318
Drug: BION-1301 Single Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC injection administration as a single dose using vials or pre-filled syringes (PFS) (Part 4 only).
Study: NCT02853071
Drug: standard practice
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard practice
Study: NCT00002773
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00635986
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mcg Fentanyl intravenous or epidural route
Study: NCT00006390
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02088892
Drug: BCG Tice
Normalized name: BCG TICE 50MG/AMP VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injection
Study: NCT02482753
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally twice per week (BIW)
Study: NCT06454643
Drug: Flucloxacillin and gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: This intervention aimed to investigate the effectiveness of administering gentamicin in reducing the incidence of SSI.
Study: NCT02875717
Drug: low molecular weight heparin
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03231397
Drug: Assess AAA rupture risk by PET-CTA scans
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assess AAA rupture risk by PET-CTA scans
Study: NCT00005822
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients receive doxorubicin IV continuously over 72 hours on days 1-3 of course 1. For all subsequent courses, patients receive doxorubicin as in course 1. Treatment repeats every 21 days for 5 courses in the absence of disease progression or unacceptable toxicity.
Study: NCT02135016
Drug: 0.9% normal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: epidural anesthesia with 0.9% normal saline 5ml before propofol TCI
Study: NCT04595929
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Day 1 q2w: 200 mg/m² IV over 30 minutes
Study: NCT04595929
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy according to indications.
Study: NCT01398657
Drug: Adjuvant Androgen-Deprivation Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-term adjuvant androgen-deprivation therapy
Study: NCT01088711
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly placebo capsule
Study: NCT03743727
Drug: Combined therapy LDV and SOF
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive ledipasvir/sofosbuvir fixed dose combination for 12 weeks. Patients weighing 35 kg or more will receive the adult dose: ledipasvir (90 mg)/sofosbuvir (400 mg). Patients weighing below 35 kg will receive half the adult dose: ledipasvir (45 mg)/sofosbuvir (200 mg).
Study: NCT00355771
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet OD in the morning for 8 weeks
Study: NCT02561546
Drug: p53 gene therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trans-catheter embolization (TAE) combined with recombinant adenoviral human p53 gene (rAd-p53) will be given one per month
Study: NCT02561546
Drug: Trans-catheter embolization
Normalized name: HOSE ANTI-EMBOLISM CALF LEN LARGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trans-catheter embolization alone
Study: NCT00664365
Drug: GSK958108
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK958108 oral tablets will be available with dosing strengths of 1 milligram, 5 milligrams, 25 milligrams and 50 milligrams. It will be a brownish-yellow film coated round shape tablet. The tablets have to be swallowed completely with 240 milliliters of water, without chewing over a period of five minutes.
Study: NCT00664365
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets will be brownish-yellow film coated round shape tablets, administered orally. The tablets have to be swallowed completely with 240 milliliters of water, without chewing over a period of five minutes.
Study: NCT00030966
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo monthly infusion for up to 116 weeks.
Study: NCT01442649
Drug: 5-fluoro-uracil
Normalized name: Fluoro Uracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400mg/m² in bolus on D1, then 2400mg/m² over 46 h every 2 weeks up to progression or toxicity
Study: NCT00568217
Drug: Diclofenac, Paracetamol, Ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediately if temperature \> 38 degree Celsius, diclofenac suppository 1,5 mg/kg once or placebo suppository After eight hours, if temperature still \< 38 degree Celsius, acetaminophen mixture 15 mg/kg up to four times a day, or ibuprofen mixture 10 mg/kg up to four times a day, or placebo mixture up to four times a day as long as temperature \< 38 degree Celsius
Study: NCT02508103
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal Placebo spray (3x/day) self-administered during laboratory testing session and then for 4-5 days until menses begins
Study: NCT01293747
Drug: Estradiol + Progesterone
Normalized name: ESTRADIOL/PROGESTERONE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol 1 mg and progesterone 20 mg microspheres injectable aqueous suspension, intramuscular monthly injection for a total of 4 doses.
Study: NCT01293747
Drug: Estradiol + Progesterone
Normalized name: ESTRADIOL/PROGESTERONE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol 0.5 mg and progesterone 15 mg microspheres injectable aqueous suspension, intramuscular monthly injection for a total of 4 doses.
Study: NCT02906579
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02906579
Drug: IW-1973
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01481883
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule daily for 12 week trial
Study: NCT04301739
Drug: nab-paclitaxel, carboplatin, doxorubicin or epirubicin and cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: chemotherapeutics
Study: NCT04301739
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03615820
Drug: Niosomal PPE oromucoadhesive film
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Niosomal PPE oromucoadhesive film in which Propolis entrapped in niosomal vesicles and incorporated in oromucoadhesive film
Study: NCT03615820
Drug: Oromucoadhesive film
Normalized name: testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oromucoadhesive film without PPE control testing which represents Placebo group
Study: NCT00004763
Drug: Ethinyl estradiol/norethindrone
Normalized name: ETHINYL ESTRADIOL/NORETHINDRONE
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02028780
Drug: Placebo to dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT03457324
Drug: JCM-16021
Approvals — FDA: no, EMA: no, PMDA: no
Description: This prescription with seven ingredients.
Study: NCT03457324
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01602679
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
Study: NCT02966717
Drug: conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention of conventional therapy group: controlling blood pressure using amlodipine, valsartan, metoprolol and terazosin and so on , protecting the renal function using bailing capsule, alpha keto acid, low molecular weight heparin and so on.
Study: NCT02112019
Drug: hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00806208
Drug: MEDI-507
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.012 mg/kg MEDI 507 and Methylprednisolone
Study: NCT00806208
Drug: MEDI-507
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.04 mg/kg MEDI 507 and Methylprednisolone
Study: NCT00806208
Drug: MEDI-507
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12 mg/kg MEDI 507 and Methylprednisolone
Study: NCT00806208
Drug: MEDI-507
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg/kg MEDI 507 and Methylprednisolone
Study: NCT01427270
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets to match OXN or OXY taken orally every 12 hours
Study: NCT00421109
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encapsulated tablet. Once daily for 28 days
Study: NCT02033278
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion plus conventional medical treatment (as indicated by clinician)
Study: NCT00560482
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical appearing gelatin capsules containing placebo
Study: NCT01563913
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar Pill, taken for 1.5 years
Study: NCT04388124
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01817166
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a placebo treatment mimicking 100.000 UI of cholecalciferol every 14 days for a maximum of 24 months or until conversion to full multiple sclerosis has occurred.
Study: NCT03942887
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: after intravenous pulse methylprednisolone, oral prednisolone will be given at a dose of 1mg/kg daily and tapered according to the recommendations
Study: NCT03058471
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: methotrexate arm will be given methotrexate starting at 10 mg weekly to be increased to 25 mg maximum in subsequent visits gradually
Study: NCT03058471
Drug: Steroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: inj. depot methyl prednisolone 80 mg ,2 doses deep intramuscularly given one week apart to all patients who have 5 or more swollen or tender joints
Study: NCT00003032
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04462822
Drug: ADVAIR DISKUS® 250/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 inhalations of Test and Reference product in each study period
Study: NCT01014078
Drug: Azithromycin Ophthalmic Solution, 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop BID for the first 2 days and then 1 drop once a day for the remainder of the study (29 ± 1 days)
Study: NCT01014078
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop BID for the first 2 days and then 1 drop once a day for the remainder of the study (29 ± 1 days)
Study: NCT01089010
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo in capsules administered as a single oral dose.
Study: NCT02589847
Drug: Standard of Care Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care Antibiotics
Study: NCT02970539
Drug: Oraxol
Normalized name: doxycycline hyclate Oral Capsule [Oraxyl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oraxol (Paclitaxel and HM30181A) will be dosed orally. Paclitaxel will be supplied as capsules and HM30181A will be supplied as tablets.
Study: NCT02023112
Drug: ABT-450/r/ABT-267
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet; ABT-450 coformulated with ritonavir and ABT-267
Study: NCT00050479
Drug: Celecoxib (Celebrex)
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04035538
Drug: CKD-320, D012
Approvals — FDA: no, EMA: no, PMDA: no
Description: R: D012 1tablet, QD, PO T: CKD-320 2tablets, QD, PO
Study: NCT01293084
Drug: 7% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mL 7% saline inhaled once over 20 minutes
Study: NCT03147599
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01124799
Drug: TMC435
Approvals — FDA: no, EMA: no, PMDA: no
Description: one morning TMC435 dose between 75 and 150 mg and a placebo dose at noon and in the evening, for 9 days
Study: NCT01124799
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo dose in the morning, at noon and in the evening, for 9 days
Study: NCT04499196
Drug: GlucoCorticoid
Normalized name: Glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administering glucocorticoid
Study: NCT00791037
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02258906
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03001323
Drug: Standard long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discharge on once a day long-acting insulin by pen that patient is using at time of enrollment (supplied by clinic) at dose 0.3 U/kg with reduction to 0.2 U/kg for GFR \<30 ml/hr.~Fast acting insulin that patient is using will be adjusted so that total daily dose given to cover 2 or 3 meals is equal to the long-acting insulin dose. Patient will have basal bolus regimen either using carb counting or with set doses for meals.~Insulin adjustment if hypoglycemia (less than 60 mg/dl) or if fasting BG over 140 despite insulin compliance. For hypoglycemia, dose will be lowered 0.05 U/kg and for elevated fasting glucose it will be raised 0.05 U/kg.~Phone calls every month and clinic visits every 3 months for 1 year with dose adjustment as above.
Study: NCT00718523
Drug: AMG 479 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo administered Day 1 of each 21 day cycle.
Study: NCT00877539
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled, two doses 4 hours apart
Study: NCT02080364
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered orally, once daily for 18 months
Study: NCT02762708
Drug: Exendin-9,39
Approvals — FDA: no, EMA: no, PMDA: no
Description: A subset of 4 subjects who have undergone RYGB surgery will be studied 4 weeks after surgery. Subjects will be randomized to receive an infusion of either Exendin-9,39 or normal saline. Exendin-9,39 blocks the action of specific hormones called incretins that are produced by the gut in health and in larger quantities after gastric bypass surgery.
Study: NCT02762708
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: subset of 4 subjects who have undergone RYGB surgery will be studied 4 weeks after surgery. Subjects will be randomized to receive an infusion of either Exendin-9,39 or normal saline. Exendin-9,39 blocks the action of specific hormones called incretins that are produced by the gut in health and in larger quantities after gastric bypass surgery.
Study: NCT01568112
Drug: BG00012 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching BG00012
Study: NCT00784589
Drug: General Corticotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: for patients with severe pemphigus : general corticotherapy Arm : 1.5mg/kg/d for 1 month, then 1.25mg/kg/d for 1 month, then 1mg/kg/d for 1 month, then 0.75 mg/kg/d for 1 month, then 0.5 mg/kg/d for 3 months, then 0.3 mg/kg/d for 3 months, then 0.2 mg/kg/d for 4 months, then 0.1 mg/kg/d for 4 months, for patients with moderated pemphigus : general corticotherapy Arm : 1mg/kg/d for 1 month, then 0.75mg/kg/d for 1 month, then 0.5mg/kg/d for 2 months, then 0.3 mg/kg/d for 2 months, then 0.2 mg/kg/d for 3 months, then 0.1 mg/kg/d for 3 months,
Study: NCT00624832
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo of Xolair (omalizumab), by subcutaneous injection of a solution with a concentration of 125 mg/mL in a supine position.
Study: NCT04274075
Drug: GDC-9545 Tablet, Fasted: Treatment A
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dose of the GDC-9545 Phase 1 reference tablet formulation (three 10-mg tablets) administered orally with approximately 240 mL room temperature water after at least an 8-hour fast.
Study: NCT04274075
Drug: GDC-9545 Capsule, Fasted: Treatment B
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dose of the GDC-9545 Phase 3 capsule formulation (one 30-mg capsule) administered orally with approximately 240 mL room temperature water after at least an 8-hour fast.
Study: NCT04274075
Drug: GDC-9545 Capsule, Fed: Treatment C
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dose of the GDC-9545 Phase 3 capsule formulation (one 30-mg capsule) administered orally with approximately 240 mL room temperature water within 30 minutes of eating a high-fat meal.
Study: NCT01269099
Drug: IV-PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV-PCA (fentanyl 10 mcg/ml) Dose bolus-lock out time - basal = 1.5 ml - 15 min - 1.5 ml/hr
Study: NCT03181685
Drug: recombinant FSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled ovarian stimulation (COS)
Study: NCT02217852
Drug: Captopril,Hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: doses used range from 25-50mg po tid for captopril and 12.5-25mg po qd for hydrochlorothiazide. Total duration would be until completion or study or medication intolerance.
Study: NCT02217852
Drug: Beijing hypotensive No.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 pile po qd or less. Total duration would be until completion or study or medication intolerance.
Study: NCT04464408
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: (9 tablets) by mouth twice daily for one day, followed by (4 tablets) twice daily (Maximum days of therapy is 7 days)
Study: NCT02588092
Drug: ADCT-301
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT00423813
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Solution
Study: NCT00423813
Drug: Xyrem®
Approvals — FDA: no, EMA: no, PMDA: no
Description: two doses
Study: NCT00869128
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03731390
Drug: GR1405 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration according to the patient's weight. All dose groups were administered once every 2 weeks.
Study: NCT01064362
Drug: Low molecular weight heparin (LMWH)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMWH including: dalteparin, nadroparin, enoxaparin or tinzaparin (ATC:B01AB (excluding B01AB01))
Study: NCT00005802
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00005802
Drug: therapeutic hydrocortisone
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00717652
Drug: arbutin, tretinoin, triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: arbutin, tretinoin, triamcinolone
Study: NCT00717652
Drug: Triluma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroquinone, Fluoncinolone, Tretinoin
Study: NCT03510897
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: isotonic saline
Study: NCT00729300
Drug: disulfiram
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 250mg daily
Study: NCT00774072
Drug: Tobramycin (Gernebcin®)
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 ml / day in each nostril
Study: NCT00615810
Drug: Kivexa plus Sustiva
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open label once daily for oral administration
Study: NCT00352625
Drug: Ketoprofen Topical Patch 20%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03364036
Drug: Mavenclad®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received Mavenclad® 3.5 milligram per kilogram (mg/kg) of body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year.
Study: NCT00565201
Drug: Placebo and rehab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive placebo saline (100 to 360 U) injected into any of the following muscles: 30-100U in the Flex. Dig. Sublimes (3 sites), 30-100U in the flex. Carpi Rad. (3 sites), 30- 100 U flex Carpi Ulnaris (3 sites), 30-100 U in the flex Dig Superficiali ( 3 sites), 25U Prontator Teres (1 site), 25 U Brachioradialis (1 site) followed by Physical Rehabilitation: One hour session divided into 3 categories of treatment - 1.) Pre-functional/modalities for a general guideline of treatment; 2.)Repetitive task practice and strengthening; 3.)Functional activities - ADL and IADLs.
Study: NCT00734656
Drug: dutasteride + ethanol
Normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 mg dutasteride administered 2-4 days prior to ingestion of 0.8 mg/kg ethanol divided between three drinks consumed over 36 minutes
Study: NCT00734656
Drug: placebo medication + ethanol
Normalized name: ethanol Medicated Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo medication administered 2-4 days prior to ingestion of 0.8 gr/kg ethanol divided between three drinks consumed over 36 minutes